Vancouver, Canada

François Jean

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: The University of British Columbia. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: François Jean - Innovator in Antiviral Agents

Introduction

François Jean is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of antiviral research, particularly through his innovative work on antiviral agents. His research focuses on the development of effective treatments for viral infections, including those caused by coronaviruses and flaviviruses.

Latest Patents

François Jean holds a patent for "Antiviral agents, uses thereof and methods for their preparation." This patent relates to the use of cladoniamides and their derivatives as antiviral agents. The disclosure emphasizes the potential of these compounds in treating viral infections, showcasing the importance of his work in addressing public health challenges.

Career Highlights

François Jean is affiliated with the University of British Columbia, where he conducts his research. His academic background and expertise have positioned him as a leader in the field of antiviral research. With 1 patent to his name, he continues to push the boundaries of scientific knowledge and innovation.

Collaborations

Throughout his career, François has collaborated with notable colleagues, including Tirosh Shapira and Rory Long. These partnerships have enhanced his research efforts and contributed to the advancement of antiviral therapies.

Conclusion

François Jean's work in developing antiviral agents is crucial in the fight against viral infections. His innovative research and collaborations highlight the importance of scientific inquiry in improving public health outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…